摘要
目的分析调治病毒性心肌炎中药复方专利的用药配伍规律,为中药新药研发、专利保护提供参考。方法计算机检索国家知识产权局专利公布公告网站(http://epub.sipo.gov.cn)建库至2018年7月31日调治病毒性心肌炎的中药复方专利数据。采用中医传承辅助平台(V2.5)进行频次统计、关联规则、复杂网络、熵聚类等分析。结果纳入中药复方专利179项,涉及药物712味,最常见的主治证候为气阴两虚证(52次,29.05%);最常用的药物为麦冬(75次,41.90%)、五味子(75次,41.90%),最常用的对药为麦冬-五味子(49次,27.37%),常用的角药有麦冬-丹参-五味子(30次,16.76%)、麦冬-党参-五味子(25次,13.97%)等;高置信度关联规则有'炙甘草-当归→五味子''麦冬-黄连→五味子''黄连-党参→五味子'等;核心药物为麦冬、五味子、丹参等;新处方有'板蓝根-薄荷-荆芥-黄芩-磁石''半夏-白术-炙甘草-茯神-远志-当归''丹参-黄连-连翘-党参-柴胡'等。结论临床研发调治病毒性心肌炎中药可针对其常见主治证候,活用益气、养阴、活血、祛瘀、行气之品,灵活处方以提高临床疗效。
Objective To analyze the medication and compatibility rules of compound TCM patents for treatment of viral myocarditis;To provide references for research and development of new TCM and patent protection.Methods All compound TCM patents related to the treatment of viral myocarditis were extracted from the national patent database(http://epub.sipo.gov.cn)from the establishment of the database to 31 st,July 2018.TCM Inheritance Support System(V2.5)was used to conduct frequency statistics,association rules,complex network,and entropy clustering.Results Totally 179 compound TCM patents were included,involving 712 kinds of Chinese materia medica,and the most common syndrome was deficiency of both qi and yin syndrome(52 times,accounting for29.05%).The most common Chinese materia medica was Ophiopogonis Radix(75 times,accounting for 41.90%)and Schisandrae Chinensis Fructus(75 times,accounting for 41.90%).The most common medical combination was Ophiopogonis Radix-Schisandrae Chinensis Fructus(49 times,accounting for 27.37%).The most common triple combinations were Ophiopogonis Radix-Salviae Miltiorrhizae Radix et Rhizoma-Ophiopogonis Radix(30 times,accounting for 16.76%)and Ophiopogonis Radix-Codonopsis Radix-Ophiopogonis Radix(25 times,accounting for13.97%).Confidence-based association rules were'Glycyrrhizae Radix et Rhizoma Praeparata cum Melle-Angelicae Sinensis Radix→Schisandrae Chinensis Fructus','Ophiopogonis Radix-Coptidis Rhizoma→Schisandrae Chinensis Fructus','Coptidis Rhizoma-Codonopsis Radix→Schisandrae Chinensis Fructus'.The core medicines were Ophiopogonis Radix,Schisandrae Chinensis Fructus,and Salviae Miltiorrhizae Radix et Rhizoma.The new prescriptions were'Isatidis Radix-Menthae Haplocalycis Herba-Schizonepetae Herba-Astragali Radix-Magnetitum','Pinelliae Rhizoma-Atractylodis Macrocephalae Rhizoma-Glycyrrhizae Radix et Rhizoma Praeparata cum Melle-Poria-Polygalae Radix-Angelicae Sinensis Radix',and'Salviae Miltiorrhizae Radix et Rhizoma-Coptidis Rhizoma-Forsythiae Fructus-Codonopsis Radix-Bupleuri Radix'.Conclusion Clinical research and development of new TCM for the treatment of viral myocarditis should give priority to main syndromes,flexibly using medicines for tonifying qi,nourishing yin,activating blood circulation,dissipating blood stasis,and motivating qi to promote clinical efficacy.
作者
但文超
何庆勇
王阶
郭建波
曲艺
DAN Wenchao;HE Qingyong;WANG Jie;GUO Jianbo;QU Yi(Guang'anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China;Beijing University of Chinese Medicine,Beijing 100029,China)
出处
《中国中医药信息杂志》
CAS
CSCD
2019年第7期94-98,共5页
Chinese Journal of Information on Traditional Chinese Medicine
基金
北京市科技新星计划(Z181100006218035)
中央本级重大增减支项目名贵中药资源可持续利用能力建设项目(2060302)
关键词
病毒性心肌炎
专利
配伍规律
中药复方
证候
viral myocarditis
patents
compatibility rules
compound TCM
syndromes
作者简介
通讯作者:何庆勇,E-mail:heqingyongg@163.com
